Status:
UNKNOWN
Dexmedetomidine Prevents Postoperative Delirium After Deep Brain Stimulation in Patients With Parkinson's Disease
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Dexmedetomidine
Postoperative Delirium
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
Postoperative delirium (POD) is a common complication, and the incidence of POD after deep brain stimulation(DBS) implementation ranges from 10% to 40%. Previous studies suggested that aging and exist...
Eligibility Criteria
Inclusion
- Patients with Parkinson's Disease
- Exist non-motor symptoms
- Undergoing selective DBS.
- Age ≥60 years.
- Obtain written informed consent.
Exclusion
- preoperative severe cognitive impairment (Montreal Cognitive Assessment, MoCA\< 18)
- history of psychoactive
- allergic or intolerant to dexmedetomidine
- severe bradycardia (heart rate lower than 40 beats/min) or sick sinus syndrome, second-degree or third-degree atrioventricular block
- severe hepatic dysfunction (Child-Pugh class C)
- severe renal dysfunction requiring renal replacement therapy before the surgery
- medical records documented inability to communicate in the preoperative period due to language barrier or other situations.
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT05197439
Start Date
December 1 2023
End Date
December 31 2024
Last Update
June 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tian Tan Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100160